Urigen Pharmaceuticals Announces a Partial Debt Restructuring

SAN FRANCISCO--(Business Wire)--
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company
focused on the development of treatments for urological disorders and pain,
announced today that the Company has initiated the restructuring of its debts.

"As we continue to pursue strategic alternatives, we are pleased that the
majority of our unsecured note holders have converted $537,000 of their notes
and $109,587 of accrued interest into common stock of the Company," said
Urigen`s CFO Martin E. Shmagin. "We are also pleased that our lead institutional
investor, Platinum-Montaur Life Sciences LLC, has agreed to a six month
extension on the maturity of our secured debt."

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to
the development and commercialization of therapeutic products for urological
disorders. Urigen's two lead programs target significant unmet medical needs and
major market opportunities in urology. Urigen's URG101, a proprietary
combination of approved drugs that is instilled into the bladder, targets
painful bladder syndrome, which affects approximately 10.5 million men and women
in North America. Urigen's URG301, a proprietary dosage form of an approved drug
that is locally delivered to control urinary urgency, targets acute urgency in
females diagnosed with an overactive bladder, another major unmet need that is
insufficiently managed by presently available overactive bladder drugs. For
further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may
be identified by the use of forward-looking terminology such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend," "may," "might,"
"plan," "potential," "predict," "should," or "will," or the negative thereof or
other variations thereon or comparable terminology. Urigen has based these
forward-looking statements on current expectations, assumptions, estimates and
projections. While Urigen believes that these expectations, assumptions,
estimates and projections are reasonable, such forward-looking statements are
only predictions and involve known and unknown risks and uncertainties, many of
which are beyond its control. Given these risks and uncertainties, investors and
security holders are cautioned not to place undue reliance on such
forward-looking statements. Urigen does not undertake any obligation to update
any such statements or to publicly announce the results of any revisions to any
such statements to reflect future events or developments.

Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, 415-781-0350
Chief Financial Officer
http://www.urigen.com

Copyright Business Wire 2009